抗血管生成药物在铂耐药卵巢癌中的应用进展

doi:10.11904/j.issn.1002-3070.2020.01.011

Abstract

Abstract: Chemotherapy drugs are very limited in the treatment of platinum-resistant ovarian cancer.In recent years,several trials have shown that antiangiogenic drugs can effectively improve the prognosis of patients with drug-resistant ovarian cancer.According to different mechanisms of action,antiangiogenic drugs are divided into vascular endothelial growth factor inhibitors,vascular endothelial growth factor receptor inhibitors,tyrosine kinase inhibitors and integrin inhibitors,and described the research progress of antiang iogenic drugs in the treatment of platinum-resistant ovarian cancer.

Key words: Ovarian cancer, Antiangiogenic drugs, Drug resistance

CLC Number:

R737.31

LIANG Yongqin, ZHAO Hongwei. Application progress of antiangiogenic drugs in platinum-resistant ovarian cancer[J]. Journal of Practical Oncology, 2020, 34(1): 60-63.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2020.01.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2020/V34/I1/60

References

1 赵玲军.卵巢癌靶向治疗新进展[J].现代实用医学,2019,31(7):854-857.
2 罗丹,孔民.复发性卵巢癌治疗的研究进展[J].癌症进展,2019,17(17):2003-2006.
3 Takasaki K,Miyamoto M,Takano M,et al.Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer:a retrospective analysis[J].Cancer Chemother Pharmacol,2018,81(5):809-814.
4 张志方,席晓薇,祖剑飞,等.复发性上皮性卵巢癌的药物治疗及进展[J].实用药物与临床,2019,22(5):452-455.
5 Gadducci A,Lanfredini N,Sergiampietri C.Antiangiogenic agents in gynecological cancer:State of art and perspectives of clinical research[J].Crit Rev Oncol Hematol,2015,96(1):113-128.
6 Randall LM,Monk BJ.Bevacizumab toxicities and their management in ovarian cancer[J].Gynecol Oncol,2010,117(3):497-504.
7 Crothey A,Ellis LM.Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies[J].Cancer J,2008,14(3):170-177.
8 Pujade LE,Hilpert F,Weber B,et al.Bevacizumab combined with chemotherapy for platinumresistant recurrent ovarian cancer:the AURELIA open-label randomized phase III trial[J].Clin Oncol,2014,32(13):1302-1308.
9 Broglio KR,Berry DA.Detecting an overall survival benefit that is derived from progression-free survival[J].J Natl Cancer Inst,2009,101(23):1642-1649.
10 Kenro C,Sachiho N,Tomoyuki K,et al.Bevacizumab improves overall survival in platinum refractory ovarian cancer patients:A retrospective study[J].Taiwan J Obstet Gynecol,2018,57(6):819-824.
11 Barber EL,Zsiros E,Lurain JR,et al.The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer[J].Gynecol Oncol,2013,24(3):258-264.
12 卢淮武,霍楚莹,林仲秋.《2019NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J].中国实用妇科与产科杂志,2019,35(5):536-546.
13 Cohen S,Schwartz M,Dottino P,et al.Use of a multi-drug regimen gemcitabine,5-fluorouracil,irinotecan,cisplatin,bevacizumab,docetaxel,and cyclophosphamide(GFIP/BDC)for heavily pretreated relapsed epithelial ovarian,fallopian tube and primary peritoneal cancer[J].Ovarian Res,2019,12(1):36.
14 张亚会,孙文广.生育三烯酚抗肿瘤作用研究进展[J].癌症进展,2017,15(6):614-617.
15 Caroline BT,Rikke FA,Karina DS,et al.Delta tocotrienol in recurrent ovarian cancer.A phase II trial[J].Pharmacol Res,2019,141:392-396.
16 李瑶,朱壮彦.生育三烯酚在宫颈癌中的研究进展[J].临床医药文献电子杂志,2017,4(14):2754-2755.
17 Wang HP,Sun SL,Zhang Y,et al.Improved drug targeting to liver tumor by sorafenib-loaded folate-decorated bovine serum albumin nanoparticles[J].Drug Deliv,2019,26(1):89-97.
18 Radoslav C,Felix H,Sven M,et al.Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer(TRIAS):a multicentre,randomised,double-blind,placebo-controlled,phase 2 trial[J].Lancet,2018,19(9):1247-1258.
19 Miao M,Deng G,Luo S,et al.A phase II study of apatinib in patients with recurrent epithelial ovarian cancer[J].Gynecol Oncol,2018,148(2):286-290.
20 Chun YL,Yin W,Ying X,et al.Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer(AEROC):a phase 2,single-arm,prospective study[J].Lancet Oncol,2018,19(9):1239-1246.
21 Liu JF,Tolaney SM,Birrer M,et al.A Phase 1 trial of the poly(ADP-ribose)polymerase inhibitor olaparib(AZD2281)in combination with the anti-angiogenic cediranib(AZD2171)in recurrent epithelial ovarian or triple-negative breast cancer[J].Eur J Cancer,2013,49(14):2972-2978.
22 Monk BJ,Poveda A,Vergote I,et al.Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer(TRINOVA-1):a randomised,multicentre,double-blind,placebo-controlled phase 3 trial[J].Lancet Oncol,2014,15(8):799-808.
23 Marth C,Vergote I,Scambia G,et al.ENGOT-ov-6/TRINOVA-2:Randomised,double-blind,phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer[J].Eur J Cancer,2017,70(complete):111-121.
24 Scalici JM,Harrer C,Allen A,et al.Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin[J].Gynecol Oncol,2014,132(2):455-461.

[1]	HUANG Li, LONG Youmei, FU Yixia, XIA Liangbin. Effect of pterostilbene on apoptosis and glycolysis of ovarian cancer SKOV3 cells and its mechanism [J]. Journal of Practical Oncology, 2019, 33(6): 502-507.
[2]	DENG Mingxin, ZHANG Ying. Research progress of circRNAs and ovarian cancer [J]. Journal of Practical Oncology, 2019, 33(6): 549-552.
[3]	ZHANG Huiting, LOU Ge. Research progress in 3D cell culture model of ovarian cancer tumor microenvironment [J]. Journal of Practical Oncology, 2019, 33(6): 557-560.
[4]	SONG Ling, FU Qiong. Astragalin inhibits hypoxia-induced proliferation and invasion of ovarian cancer cells by up-regulating PHD2 [J]. Journal of Practical Oncology, 2019, 33(5): 407-414.
[5]	HUANG Xianbo, SHI Ting, YE Xiujin. Progress in the treatment of acute T lymphoblastic leukemia by targeting PI3K/AKT/mTOR pathway [J]. Journal of Practical Oncology, 2019, 33(5): 451-455.
[6]	ZHANG Beilei, LI Yi, WU Tao, JIANG Feng, ZHAO Hongxi, LI Yanhong. Mechanism study of sanguinarine inhibiting tumor growth of ovarian cancer by apoptosis induction [J]. Journal of Practical Oncology, 2019, 33(4): 305-309.
[7]	LV Bowen, QIAN Jun, WANG Jie, QIAN Jingrong, LU Yingying, SU Liju, YANG Tongshu, LI Wenhui. Expression of MiR-455-5p in epithelial ovarian cancer and its target gene function [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 115-121.
[8]	SONG Ling, FU Qiong. Study of the effect of astragalin on proliferation of ovarian cancer cells by inhibiting the glycolytic pathway induced Via HIF-1α [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 503-509.
[9]	JIANG Liangliang, WANG Jing. Progress in diagnosis and treatment of distant metastasis of epithelial ovarian cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 480-482.
[10]	LIANG Guanying,CHI Qiujun,LI Xiaomei. Effect and mechanism of Vorinostat on the proliferation and apoptosis of ovarian cancer SKOV3 cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 298-302.
[11]	LI Wenhui, LV Bowen, QIAN Jun, SU Liju, YANG Tongshu, QIAN Jingrong, WANG Jie. Effect of microRNA-150 on proliferation,apoptosis,invasion and metastasis of epithelial ovarian cancer cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 208-213.
[12]	BI Qiling, ZHOU Lihong, HAN Yimin. Research progress of HOX gene and gynecologic tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 140-143.
[13]	LIU Xin, XU Yingjuan, YANG Chang, LOU Ge. Research progress on cadherins and integrins in ovarian epithelial cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 548-553.
[14]	SUN Lina, ZHAO Xiaodi, LU Yuanyuan, WANG Xin. Research progress of LncRNA and chemotherapy resistance in gastrointestinal neoplasms [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 448-453.
[15]	ZENG Yulan,LIU Yangyang,LIANG Jinyan,GU Feifei,LIU Li. Advances in drug resistance mechanism of immunological checkpoint inhibitors and post-drug resistant therapeutic strategy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 353-358.

Application progress of antiangiogenic drugs in platinum-resistant ovarian cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments